Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
Ahmet Özet, Faysal Dane, Nuri Faruk Aykan, Şuayib Yalçın, Türkkan Evrensel, Metin Özkan, Bülent Karabulut, Merve Nur Ormeci, Ozan Atasev, Loïck Vidot, İrfan Çiçin, Ahmet Özet, Faysal Dane, Nuri Faruk Aykan, Şuayib Yalçın, Türkkan Evrensel, Metin Özkan, Bülent Karabulut, Merve Nur Ormeci, Ozan Atasev, Loïck Vidot, İrfan Çiçin
Abstract
Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with ≥2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting. Clinical Trial Registration: NCT03306394 (ClinicalTrials.gov).
Keywords: PRECONNECT study; Turkish population; metastatic colorectal cancer; real-world data; trifluridine/tipiracil.
Source: PubMed